Cyclodextrins in drug delivery: An updated review

AAPS PharmSciTech

Volumn 6, Issue 2, 2005, Pages

  Challa, Rajeswari ^a   Ahuja, Alka ^a   Ali, Javed ^a   Khar, R K ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Cyclodextrins; Drug delivery; Drug formulation; Excipients; Novel delivery systems

Indexed keywords

2 HYDROXYL 3 TRIMETHYLAMMONIOPROPYL BETA CYCLODEXTRIN; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALPHA CYCLODEXTRIN; BETA CYCLODEXTRIN; CARBOXYMETHYL BETA CYCLODEXTRIN; CARBOXYMETHYLETHYL BETA CYCLODEXTRIN; CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; DI O HEXANOYL BETA CYCLODEXTRIN; DIETHYL BETA CYCLODEXTRIN; DIMETHYL BETA CYCLODEXTRIN; EXCIPIENT; GAMMA CYCLODEXTRIN; GENE PRODUCT; GLUCOSYL BETA CYCLODEXTRIN; HYDROXYETHYL BETA CYCLODEXTRIN; LIPOSOME; MALTOSYL BETA CYCLODEXTRIN; METHYL BETA CYCLODEXTRIN; MICROSPHERE; NANOPARTICLE; PEPTIDE; PROTEIN; RANDOMLY DIMETHYLATED BETA CYCLODEXTRIN; RANDOMLY METHYLATED BETA CYCLODEXTRIN; SULFOBUTYLETHER BETA CYCLODEXTRIN; TRI O BUTYRYL BETA CYCLODEXTRIN; TRI O ETHYL BETA CYCLODEXTRIN; TRI O METHYL BETA CYCLODEXTRIN; TRI O VALERYL BETA CYCLODEXTRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

COMPLEX FORMATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; GENE DELIVERY SYSTEM; MATERIALS HANDLING; MICROCAPSULE; PATENT; PROBLEM SOLVING; REVIEW;

EID: 27744575591     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt060243     Document Type: Review

References (242)

1. Loftsson T, Brewester M. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017-1025.
2. Endo T, Nagase H, Ueda H, Kobayashi S, Nagai T. Isolation, purification, and characterization of Cyclomaltodecaose (curly epsilon-Cyclodextrin), Cyclomaltoundecaose (zeta-Cyclodextrin) and Cyclomaltotridecaose (é-Cyclodextrin). Chem Pharm Bull (Tokyo). 1997;45:532-536.
3. Endo T, Nagase H, Ueda H, Shigihara A, Kobayashi S, Nagai T. Isolation, purification and characterization of Cyclomaltooctadecaose (v-Cyclodextrin), Cyclomaltononadecaose (xi-Cyclodextrin), Cyclomaltoeicosaose (o-Cyclodextrin) and Cyclomaltoheneicosaose (ã-Cyclodextrin, Chem Pharm Bull (Tokyo). 1998;46:1840-1843.
4. Miyazawa H, Ueda H, Nagase T, Endo T, Kobayashi S, Nagai T. Physicochemical properties and inclusion complex formation of δ-cyclodextrin. Eur J Pharm Sci. 1995;3:153-162.
5. Szejtli J. Cylodextrin in drug formulations: Part I. Pharm Technol Int. 1991;3:15-23.
6. Szente L, Szejtli J, Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev. 1999;36:17-38.
7. Matsuda H, Arima H. Cyclodextrins in transdermal and rectal delivery. Adv Drug Deliv Rev. 1999,36:81-99.
8. Higuchi T, Connors KA. Phase-solubility techniques. Adva Anal Chem Instr. 1965;4:212-217.
9. Rajewski RA, Stella VJ. Phamaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci. 1996;85:1142-1168.
10. Hersey A, Robinson BH, Kelly HC. Mechanism of inclusion compound formation for binding of organic dyes, ions and surfactants to alpha cyclodextrin studied by kinetic methods based on competition experiments. J Chem Soc, Faraday Trans 1. 1986;82:1271-1287.
11. Cramer F, Saenger W, Satz HC. Inclusion compounds. XIX.The formation of inclusion compounds of alpha cyclodextrin in aqueous solutions, thermodynamics and kinetics. J Am Chem Soc. 1967;89:14-20.
12. Uekama K, Otagiri M. Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carrier Sys. 1987;3:1-40.
13. Szejtli J. Medicinal applications of cyclodextrins, Med Res Rev. 1994:14:353-386.
14. Thomson DO. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carr Sys. 1997;14:1-104.
15. Jayachandra Babu R, Pandit JK Cyclodextrin inclusion complexes: oral applications. Eastern Pharmacist. 1995;38:37-42.
16. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci. 1997;86:147-162.
17. Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res. 1997;14:556-567.
18. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems, Chem Rev, 1998;98:2045-2076.
19. Loftsson T, Ólafsson JH. Cyclodextrins: new drug delivery system in dermatology. Int J Dermatol. 1998;37:241-246.
20. Loftsson T. Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers. Pharmazie. 1998;53:733-740.
21. Castillo JA, Canales JP, Garcia JJ, Lastres JL, Bolas F, Torrado JJ. Preparation and characterization of albendazole beta-cyclodextrin complexes. Drug Dev Ind Pharm. 1999;25:1241-1248.
22. Diaz D, Escobar Llanos CM, Bernad MJB. Study of the binding in an aqueous medium of inclusion complexes of several cyclodextrins involving fenoprofen calcium. Drug Dev Ind Pharm. 1999;25:107-110.
23. Mura P, Faucci MT, Parrini PL, Furlanetto S, Pinzauti S. Influence of the preparation method on the physicochemical properties of ketoprofen-cyclodextrin binary systems. Int J Pharm. 1999;179:117-128.
24. Nesna N, Lou J, Breslow R. The binding of cocaine to cyclodextrins. Bioorg Med Chem Lett. 2000;10:1931-1933
25. Arias-Blanco MJA, Moyano JR, Martinez JIP, Gines JM. Study of inlusion complex of gliclazide in α-cyclodextrin. J Pharm Biomed Anal. 1998;18:275-279.
26. Ueda H, Wakamiya T, Endo H, Nagase H, Tomono K, Nagai T. Interaction of cyclomaltononaose (delta-CD) with several drugs. Drug Dev Ind Pharm. 1999;25:951-954.
27. Akasaka H, Endo T, Nagase H, Ueda H, Kobayashi S. Complex formation of cyclomaltononaose delta-cycodextrin (delta-CD) with macrocyclic compounds. Chem Pharm Bull (Tokyo). 2000;48:1986-1989.
28. Mura P, Adragna E, Rabasco AM, et al. Effects of the host cavity size and the preparation method on the physicochemical properties of ibuproxam-cyclodextrin systems. Drug Dev Ind Pharm. 1999;25:279-287.
29. Lutka A. Investigation of interaction of promethazine with cyclodextrins in aqueous solution. Acta Pol Pharm. 2002;59:45-51.
30. Nagase Y, Hirata M. Wada K, et al. Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether beta-cyclodextrin. Int J Pharm. 2001;229:163-172.
31. Jain AC, Adeyeye MC. Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether beta-cyclodextrins (SBE) and danazol-SBE inclusion complexes. Int J Pharm. 2001:212:177-186.
32. Loftsson T, Peterson DS. Cyclodextrin solubilization of ETH-615, a zwitterionic drug. Drug Dev Ind Pharm. 1998;24:365-370.
33. Dalmora MEA, Oliveira AG. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in hexadecyltrimethylammonium bromide based microemulsion. Int J Pharm. 1999;184:157-164.
34. McCandless R, Yalkowsky SH. Effect of hydroxypropyl-beta-cyclodextrin and pH on the solubility of levemopamil HCl. J Pharm Sci. 1998;87:1639-1642.
35. Kim Y, Oksanen DA, Massefski W, Blake JF, Duffy EM, Chrunyk B. Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether. J Pharm Sci. 1998;87:1560-1567.
36. Tros de Ilarduya MC, Martin C, Goni MM, Martinez-Oharriz MC. Solubilization and interaction of sulindac with beta-cyclodextrin in the solid state and in aqueous solution. Drug Dev Ind Pharm. 1998;24:301-306.
37. Diaz D, Bernad MJB, Mora JG, Llaons CME. Solubility, 1H-NMR, and molecular mechanics of mebendazole with different cyclodextrins, Drug Dev Ind Pharm. 1999;25:111-115.
38. Zarzycki PK, Lamparczyk H. The equilibrium constant of β-cyclodextrin-phenolphtalein complex; influence of temperature and tetrahydrofuran addition. J Pharm Biomed Anal. 1998;18:165-179.
39. Jain AC, Adeyeye MC. Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether beta-cycloclextrins (SBE) and danazol-SBE inclusion complexes. Int J Pharm. 2001;212:177-186
40. Chowdary KPR, Nalluri BN, Nimesulide and beta-cyclodextrin inclusion complexes: physicochemical characterization and dissolution rate studies. Drug Dev Ind Pharm. 2000;26:1217-1220.
41. Palmeiri GF, Angeli DG, Giovannnucci G, Martelli S. Inclusion of methoxytropate in β-and hydroxylpropyl β-cyclodextrins: Comparision of preparation methods. Drug Dev Ind Pharm. 1997;23:27-37.
42. 2 in β-cyclodextrin: evaluation of different complexation methods. Drug Dev Ind Pharm. 1993:19:875-885.
43. Moyano JR, Arias MJ, Gines JM, Perez JI, Rabasco AM. Dissolution behavior of oxazepam in the presence of cyclodextrins: evaluation of oxazepam dimeb binary system. Drug Dev Ind Pharm. 1997:23:379-385.
44. Pose-Vilamovo B, Perdomo-Lopez I, Echezarreta-Lopez M, Schroth-Pardo P, Estrada E, Torres-Labandeira JJ. Improvement of water solubility of sulfamethizole through its complexation with β-and hydroxypropyl-β-cyclodextrin - Characterization of the interaction in solution and in solid state. Eur J Pharm Sci. 2001;13:325-331.
45. Mitrevej A, Sinchaipanid N, Junyaprasert V, Warintornuwat L. Effect of grinding of β-cyclodextrin and glibenclamide on tablet properties. Drug Dev Ind Pharm. 1996-122:1237-1241.
46. Senoferjan AM, Nanjundaswamy NG, Mahesh S, Murthy SN. Formulation and evaluation of β-cyclodextrin complexes of tenoxicam. Indian J Pharm Sci. 2000;62:119-121.
47. Loftsson T, Guomundsdottir TK, Frioriksdottir H. The influence of water-soluble polymers and pH on hydroxypropyl-α-cyclodextrin complexation of drugs. Drug Dev Ind Pharm. 1996;22:401-406.
48. Nath BS, Shivkumar HN. A 2(3) Factorial studies on factors influencing Meloxicam β-cyclodextrin complexation for better solubility. Indian J Pharm Sci. 2000;62:129-132.
49. Cappello B, Carmignani C, Iervolino M, La Rotonda MI, Saettone MF. Solubilization of tropicamide by hydroxypropyl-beta-cyclodextrin and water-soluble polymers: in vitro/ in vivo studies. Int J Pharm. 2001;213:75-81.
50. Faucci MT. Mura P. Effect of water-soluble polymers on naproxen complexation with natural and chemically modified beta-cyclodextrins. Drug Dev Ind Pharm. 2001;27:909-917.
51. Granero G, de Bertorello NM, Longhi M. Solubilization of a naphthoquinone derivative by hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and polyvinylpyrrolidone (PVP-K30). The influence of PVP-K30 and pH on solubilizing effect of HP-beta-CD. Boll Chim Farm. 2002:141:63-66.
52. Pedersen M. Effect of hydrotropic substances on the complexation of clotrimazole with beta cyclodextrin. Drug Dev Ind Pharm. 1993;19:439-448.
53. Veiga F, Fernandes C, Maincent P. Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary systems. Drug Dev Ind Pharm. 2001;27:523-532.
54. Tokumura T, Nanda M, Tsushima Y, et al. Enhancement of bioavailability of cinnarizine from its betacyclodextrin complex on oral administration with DL-phenylalanine as a competing agent. J Pharm Sci. 1986;75:391-394.
55. Muller BW, Albers E. Effect of hydrotropic substances on the complexation of sparingly soluble drugs with cyclodextrin derivatives and the influence of cyclodextrin complexation on the pharmacokinetics of the drugs. J Pharm Sci. 1991;80:599-604.
56. Redenti E, Szente L, Szetli J. Drug/cyclodextrin/hydroxy acid multicomponent systems, Properties and pharmaceutical applications. J Pharm Sci. 2000;89:1-8.
57. Li P, Zhao L, Yalkowsky SH. Combined effect of cosolvent and cyclodextrin on solubilization of nonpolar drugs. J Pharm Sci. 1999;88:1107-1111.
58. Miyake K, Irie T, Arima H, et al. Characterization of itraconazole/ 2-hydroxypropyl-beta-cyclodextrin inclusion complex in aqueous propylene glycol solution. Int J Pharm. 1999;179:237-245.
59. Blanchard J. Stefan P. Some important considerations in the use of cyclodextrins. Pharm Res. 1999;16:1796-1798.
60. Muller BW, Brauns U. Hydroxypropyl-beta-cyclodextrin derivatives: influence of average degree of substitution on complexing ability and surface activity. J Pharm Sci. 1986;75:571-572.
61. Zia V, Rajeswski RA, Bornancini ER, Luna EA, Stella VJ. Effect of alkyl chain length and degree of substitution on the complexation of sulfoalkyl ether beta-cyclodextrins with steroids. J Pharm Sci 1997;86:220-224
62. CycloLab Cyclodextrin Research & Development Laboratory Web site. Available at: http,://www.cyclolab.hu. Accessed May 25, 2005.
63. Wacker-Chemie GmbH Products and Trademarks Web site. Available at: http:/ /www.wacker com. Accessed May 25, 2005.
64. Sigma-Aldich Web site. Available at: http://www.sigmaaldrich.com/. Accessed May 25, 2005.
65. CyDex Inc Web site. Available at: http://www.cydexinc.com. Accessed May 25, 2005.
66. Inc CTC. Web site. Available at: http://www.cyclodex.com. Accessed May 25, 2005.
67. Cyclodextrins for Pharmaceutical Applications [technical brochure]. 2000; Available at: http://www.ispcorp.com/products/pharma/content/ forwhatsnew/cyclodex/cyclodex.pdf. Accessed May 25, 2005.
68. Mosher G, Thompson DO. Complexation and Cyclodextrins. In: Swarbrick J, Boylan JC, eds. Encyclopedia of Pharmaceutical Technology 2nd ed. New York, NY: Marcell Dekker; 2002:531-558.
69. Pitha J, inventor. Pharmaceutical preparations containing cyclodextrin derivatives.. US patent 4 727 064. February 23, 1988.
70. Tasic LM, Jovanovic MD, Djuric ZR. The influence of beta-cyclodextrin on the solubility and dissolution rate of paracetamol solid dispersions. J Pharm Pharmacol. 1992:44:52-55.
71. Sanghavi NM, Choudhari KB, Matharu RS, Viswanathan L. Inclusion complexation of Lorazepam with beta-cyclodextrin. Drug Dev Ind Pharm. 1993:19:701-712.
72. Ahn HJ, Kim KM, Choi SJ, Kim CK. Effects of cyclodextrin derivatives on bioavailability of ketoprofen. Drug Dev Ind Pharm. 1997;23:397-401.
73. Dhanaraju MD, Santil Kumaran K, Baskaran T, Moorthy MSR. Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin. Drug Dev Ind Pharm. 1998:24:583-587.
74. Veiga MD, Diaz PJ, Ahsan F. Interactions of griseofulvin with cyclodextrins in solid binary systems. J Pharm Sci. 1998;87:891-900.
75. Becket G, Schep LJ, Tan MY. Improvement of the in vitro dissolution of praziquantal by complexation with alpha-, beta- and gamma-cyclodextrins. Int J Pharm. 1999;179:65-71.
76. Lotter J, Krieg HM, Keizer K, Breytenbach JC. The influence of beta-cyclodextrin on the solubility of chlorthalidone and its enantiomers, Drug Dev Ind Pharm. 1999,25:879-884.
77. Askrabic JM, Rajic DS, Tasic L, Djuric S, Kasa P, Hodi KP. Etodolac and solid dispersion with β-cyclodextrin. Drug Dev Ind Pharm. 1997;23:1123-1129.
78. Cavallari C, Abertini B, Rodriguez MLG, Rodriguez L. Improved dissolution behavior of steam granulated piroxicam, Eur J Pharm Biopharm. 2002;54:65-73.
79. Chowdary KPR, Rao SS. Investigation of dissolution enhancement of itraconazole by complexation with β-, and hydroxypropyl-β-cyclodextrins. Indian J Pharm Sci. 2001;63:438-441.
80. Ghorab MK, Adeyeye MC. Enhancement of ibuprofen dissolution via wet granulation with beta cyclodextrin. Pharm Dev Technol. 2001;6:305-314.
81. Arias MJ, Moyano JR, Munoz P, Gines JM, Justo A, Giordano F. Study of omeprazole-gamma-cyclodextrin complexation in the solid state. Drug Dev Ind Pharm. 2000;26:253-259.
82. Uekama K, Fujinaga T, Hirayama F, et al. Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation. J Pharm Sci. 1983:72:1338-1341
83. Londhe V, Nagarsenker M. Comparision between Hydroxypropyl-β-cyclodextrin and polyvinyl pyrrolidine as carriers for carbamazepine solid dispersions. Indian J Pharm Sci. 1999;61:237-240.
84. Trapani G, Latrofa A, Franco M, et al. Complexation of zolpidem with 2-hydroxypropyl-β-, methyl-β-, 2-hydroxypropyl-γ-cyclodextrins: Effect on aqueous solubility, dissolution rate and ataxic activity in rats. J Pharm Sci. 2000; 89:1443-1451.
85. Latrofa A, Trapani G, Franco M, et al. Complexation of phenytoin with some hydrophilic cyclodextrins: Effect on aqueous solubility, dissolution rate and anti-covulsant activity in mice. Eur J Pharm Biopharm. 2001;52:65-73.
86. Miyake K, Arima H, Hiramaya F, et al. Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-beta-cyclodextrin, Pharm Dev Technol. 2000;5:399-407.
87. Bettinetti G, Gazzaniga A, Mura P, Giordano F, Setti M. Thermal behavior and dissolution properties of naproxen in combinations with chemically modified beta-cyclodextrins. Drug Dev Ind Pharm. 1992;18:39-53.
88. Kang J, Kumar V, Yang D, Chowdhury PR, Hohl RJ. Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. Eur J Pharm Sci. 2002;15:163-170.
89. Zhao L, Li P, Yalkowsky SH. Solubilization of fluasterone. J Pharm Sci. 1999;88:967-969.
90. Kaukonen AM, Lennernas H, Mannermaa JP. Water-soluble Beta cyclodextrin in paediatric oral solutions of spiranolactone: preclinical evalution of spiranolactone bioavailability from solutions of beta cyclodextrin derivatives in rats. J Pharm Pharmacol. 1998;50:611-619.
91. Arima H, Yunomae K, Miyake K, Irie T, Hirayama F, Uekama K. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci. 2001;90:690-701.
92. Bettinetti G, Mura P, Faucci MT, Sorrenti M, Setti M. Interaction of naproxen with noncrystalline acetyl beta- and acetyl gamma-cyclodextrins in the solid and liquid state. Eur J Pharm Sci. 2002;15:21-29.
93. Ueda H, Ou D, Endo T, Nagase H, Tomono K, Nagai T. Evaluation of a sulfobutyl ether beta-cyclodextrin as a solubilizing/stabilizing agent for several drugs. Drug Dev Ind Pharm. 1998;24:863-867.
94. Sangalli ME, Zema L, Moroni A, Foppoli A, Giordano F, Gazzania A. Influence of β-cylodextrin on the release of poorly soluble drugs from inert and hydrophilic heterogeneous polymeric matrices. Biomaterials. 2001:22:2647-2651.
95. Pina ME, Veiga F. The influence of diluent on the release of theophylline from hydrophilic matrix tablets. Drug Dev Ind Pharm. 2000:26:1125-1128.
96. Loftsson T, Stefánsson E. Effect of cyclodextrins on topical drug delivery to the eye. Drug Dev Ind Pharm. 1997;23:473-481.
97. Van Dome H. Interaction between cyclodextrins and ophthalmic drugs. Eur J Pharm Biopharm. 1993;39:133-139.
98. Loftsson T, Másson M, Stefánsson E, Cyclodextrins as permeation enhancers. 17th Pharmaceutical Technology Conference and Exhibition; March 24-26, 1997;Dublin, Ireland.
99. Loftsson T, Leeves N, Bjornsdottir B, Duffy L, Masson M. Effect of cyclodextrins and polymers on triclosan availability and substantivity in toothpastes in vivo. J Pharm Sci. 1999;88:1254-1258.
100. Willems L, Geest RV, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics, J Clin Pharm Ther. 2001;26:159-169.
101. Yang T, Hussain A, Paulson J, Abbruscato TJ, Ahsan F. Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies. Pharm Res. 2004;21:1127-1136.
102. Watanabe Y, Kiriyama M, Ito R, et al. Pharmacodynamics and pharmacokinetics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) after administration of a rectal dosage vehicle. Biol Pharm Bull. 1996;19:1059-1063.
103. Nicolazzi C, Venard V, Le Faou A, Finance C. In vitro antiviral activity of the gancyclovir complexed with beta cyclodextrin on human cytomegalovirus strains. Antiviral Res. 2002:54:121-127.
104. Blanchard J, Ugwu SO, Bhardwaj R, Dorr RT. Development and testing of an improved of phenytoin using 2-hydroxypropyl-beta-cyclodextrin. Pharm Dev Technol. 2000;5:333-338.
105. Scalia S, Villani S, Casòlari A. Inclusion complexation of the sunscreening agent 2-ethyl hexyl-p-dimethyl aminobenzoate with hydroxypropyl-β-cyclodextrin: effect on photostability. J Pharm Pharmacol. 1999;51:1367-1374.
106. Serni U. Rheumatic diseases - clinical experience with piroxicam-beta-cyclodextrin. Eur J Rheumatol Inflamm. 1993;12:47-54.
107. Kim JH, Lee SK, Ki MH, et al. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-β-cyclodextrin. Int J Pharm. 2004;272:79-89.
108. Nagase Y, Arima H, Wada K, et al. Inhibitory effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced cellular damage: In vitro and in vivo studies. J Pharm Sci. 2003;92:2466-2474.
109. Loftssona T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev. 1999;36:59-79.
110. Babu R, Pandit JK, Effect of aging on the dissolution stability of glibenclamide/beta-cyclodextrin complex. Drug Dev Ind Pharm. 1999:25:1215-1219.
111. Cwiertnia B, Hladon T, Stobiecki M. Stability of Diclofenac sodium in the inclusion complex in the beta cyclodextrin in the solid state. J Pharm Pharmacol. 1999;51:1213-1218.
112. Li J, Guo Y, Zografi G. The solid-state stability of amorphous quinapril in the presence of beta-cyclodextrins. J Pharm Sci. 2002;91:229-243.
113. Brewster ME, Loftsson T, Estes KS, Lin JL. Frionksdóttir H. Effects of various cyclodextrins on solution stability and dissolution rate of doxorubicin hydrochloride. Int J Pharm. 1992;79:289-299.
114. 7m -beta-CD and HP-beta-CD on the stability of two anti-neoplastic agents, melphalan and carmustine. J Pharm Sci. 2000;89:275-287.
115. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235:179-192.
116. Jarho P, Vander Velde D, Stella VJ. Cyclodextrin-catalyzed deacetylation of spironolactone is pH and cyclodextrin dependent. J Pharm Sci, 2000;89:241-249.
117. Sortino S, Giuffrida S, De Guldi G, et al. The photochemistry of flutamide and its inclusion complex with beta-cyclodextrin: Dramatic effect of the microenvironment on the nature and on the efficiency of the photodegradation pathways. Photochem Photobiol. 2001;73:6-13.
118. Mielcarek J. Photochemical stability of the inclusion complexes formed by modified 1, 4-dihydropyridine derivatives with beta-cyclodextrin. J Pharm Biomed Anal. 1997;15:681-686.
119. Lutka A, Koziara J. Interaction of trimeprazine with cyclodextrins in aqueous solution. Chem Pharm Bull (Tokyo), 2000;57:369-374.
120. Croyle MA, Cheng X, Wilson JM. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther. 2001;8:1281-1290.
121. 4-(6-Methoxy, 8-Quinolinyl)-1-4-Pentane diamine. Ind J Pharm Sci. 1999:61:175-177.
122. Koester LS, Guterres SS, Le Roch M, Lima VLE, Zuanazzi JA. Bassani VI. Ofloxacin/ beta-cyclodextrin complexation. Drug Dev Ind Pharm. 2001;27:533-540.
123. Choi HG, Lee BJ, Han JH, et al. Terfenadine-beta-Cyclodextrin inclusion complex with antihistaminic activity enhancement. Drug Dev Ind Pharm. 2001;27:857-862.
124. Aggarwal S, Singh PN, Mishra B. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes. Pharmazie. 2002;57:191-193.
125. Veiga F, Fernandes C, Teixeira F. Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes. Int J Pharm. 2000;202:165-171.
126. Fathy M, Sheha M. In vitro and in vivo evaluation of amylobarbitone/ hydroxypropyl-β-cyclodextrin complex prepared by a freeze-drying method. Pharmazie. 2000;55:513-517.
127. Zuo Z, Kwon G, Stevenson B, Diakur J, Wiebe LI. Flutamide- Hydroxy proyl-β-cyclodextrin complex: formulation, physical characterization, and absorption studies using the Caco-2 in vitro model. J Pharm Pharm Sci. 2000;3:220-227.
128. Yoo SD, Yoon BM, Lee HS, Lee KC. Increased bioavailability of clomipramine after sublingual administration in rats, J Pharm Sci. 1999;88:1119-1121.
129. Pitha J, Harman SM, Michel ME. Hydrophilic cyclodextrin derivatives enable effective oral administration of steroidal hormones. J Pharm Sci. 1986;75:165-167.
130. Pitha J, Anaissie EJ, Uekama K. Gamma-cyclodextrin: testosterone complex suitable for sublingual administration. J Pharm Sci. 1987;76:1788-790.
131. Farag Badawy SI, Ghorab MM, Adeyeye CM. Bioavailability of danazol-hydroxypropyl-á-cylodextrin complex by different routes of administration. Int J Pharm. 1996;145:137-143.
132. Jain AC, Aungust BJ, Adeyeye MC. Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether 7 beta-cyclodextrin (SBE 7) complexes. J Pharm Sci. 2002;91:1659-1668.
133. Garcia-Rodriguez JJ, Torrado J. Bolas F Improving bioavailability and anthelmentic activity of albendazole by preparing albendazole cyclodextrin complex. Parasite. 2001;8:S188-S190.
134. Jacobsen J, Bjerregaard S, Pedersen M. Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity-drug supersaturation, toxicity on TR146 cells and release from a delivery system. Eur J Pharm Biopharm. 1999;48:217-224.
135. Okimoto K, Ohike A, Ibuki R, et al. Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)7m-beta-CD. Pharm Res. 1999;16:549-554.
136. Okimoto K, Miyake M, Ohnishi N, et al. Design and evaluation of an osmotic pump tablet (OPT) for prednisolone, a poorly water soluble drug, using (SBE)7m-beta-CD. Pharm Res. 1998:15:1562-1568.
137. Funasaki N, Kawaguchi R, Hada S, Neya S, Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999;88:759-762.
138. Stevens DA. Intraconazole in cyclodextrin solution. Pharmacotherapy. 1999;9:603-611.
139. Shinoda T, Kagatani S, Maeda A, et al, Sugar-branched-cyclodextrins as injectable drug carriers in mice. Drug Dev Ind Pharm. 1999;25:1185-1192.
140. Blanchard J, Ugwu SO, Bhardwaj R, Dorr T. Anhydrous carbopol polymer gels for the topical delivery of oxygen/water sensitive compounds. Pharm Dev Technol. 2000;7:249-255.
141. Piel G, Evrard B, Van Hees T, Delattre L. Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution. Int J Pharm. 1999;180:41-45.
142. Sideris EE, Koupparis MA, Macheras PE. Effect of cyclodextrins on protein binding of drugs: the diflunisal/hydroxypropyl-beta-cyclodextrin model case. Pharm Res. 1994;11:90-95.
143. Grosse PY, Bressoile F, Rouanet P, Joulia JM, Pinguest F. Methyl-beta-cyclodextrin and doxorubicin pharmacokinetics and tissue concentrations following bolus injection of these drugs alone or together in the rabbit. Int J Pharm. 1999:180:215-223.
144. Hirayama F, Mieda S, Miyamoto Y, Arima H, Uekama K. Heptakis (2, 6-di-O-methyl-3-O-acetyl)-beta-cyclodextrin: a water-soluble cyclodextrin derivative with low hemolytic activity. J Pharm Sci. 1999;88:970-975.
145. Saarinen-Savolainen P, Jarvinen T, Araki-Sasaki K, Watanabe H, Urtti A. Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line. Pharm Res. 1998;15:1275-1280.
146. Siefert B, Keipert S. Influence of alpha-cyclodextrin and hydroxyalkylated β-cyclodextrin derivatives on the corneal uptake and permeation aqueous pilocarpine-HCL solutions. J Pharm Sci. 1997;86:716-720.
147. Becirevic-Lacan M, Filipovic-Grcic J. Effect of hydroxypropyl-beta-cyclodextrin on hydrocortisone dissolution from films intended for ocular drug delivery, Pharmazie. 2000;55:518-520.
148. Aktas Y, Unlu N, Orhan M, Irkec M, Hincal AA. Influence of hydroxypropyl β-cyclodextrin on the corneal permeation of pilocarpine. Drug Dev Ind Pharm. 2003;29:223-230.
149. Merkus FW, Verhoef JC, Marttin E, et al. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev. 1999;36:41-57.
150. Loftsson T, Gudmundsdottir H, Sigurjonsdottir JF, et al. Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray, Int J Pharm. 2001;1212:29-40.
151. Zhang Y, Jiang XG, Yao J. Nasal absorption enhancement of insulin by sodium deoxycholate in combination with cyclodextrins. Acta Pharmacol Sin. 2001;1221:1051-1056.
152. Srichana T, Suedee R, Reanmongkol W. Cyclodextrin as a potential drug carrier in salbutamol dry powder aerosols: the in vitro deposition and toxicity studies of the complexes. Respir Med. 2001;95:513-519.
153. Gudmundsdottir H, Sigurjonsdottir JF, Masson M, Fjalldal O, Stefansson E, Loftsson T. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. Pharmazie. 2001:56:963-966.
154. Uekama K, Kondo T, Nakamura K, et al. Modification of rectal absorption of morphine from hollow-type suppositories with a combination of alpha-cyclodextrin and viscosity-enhancing polysaccharide. J Pharm Sci. 1995;84:15-20.
155. Kowari K, Hirosawa I, Kurai H, Utoguchi N, Fujii M, Watanabe Y. Pharmacokinetics and pharmacodynamics of human chorionic gonadotropin (hCG) after rectal administration of hollow-type suppositories containing hCG. Biol Pharm Bull. 2002;25:678-681.
156. Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system. Adv Drug Deliv Rev. 1999;36:125-141.
157. Sinha VR, Nanda A, Kumria R. Cyclodextrins as sustained-release carriers. Pharmaceutical Technology. 2002; Available at: http:// www.pharmtech.com. Accessed May 25, 2005.
158. Horiuchi Y, Hirayama F, Uekama K. Slow-release characteristics of diltiazem from ethylated β-cyclodextrin complex. J Pharm Sci. 1990;79:128-132.
159. Hirayama F, Hirashima N, Abe K. Uekama K, Ijitsu T, Ueno M. Utilization of diethyl-beta-cyclodextrin as a sustained-release carrier for isosorbide dinitrate. J Pharm Sci. 1988;77:233-236.
160. Uekama K, Horikawa T, Yamanaka M, Hirayama F. Peracylated β-cyclodextrins as novel sustained-release carriers for a water-soluble drug, molsidomine. J Pharm Pharmacol. 1994:46:714-717.
161. Wang Z, Horikawa T, Hirayama F, Uekama K. Design and in vitro evaluation of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-beta-cyclodextrin and hydroxypropylcellulose. J. Pharm Pharmacol. 1993;45:942-946.
162. Quaglia F, Varricchio G, Miro A, La Rotonda MI, Larobina D, Mensitieri G. Modulation of drug release from hydroqels by using cyclodextrins: the case of nicardipine/ beta-cyclodextrin system in crosslinked polyethylenglycol. J Control Release. 2001;71:329-337.
163. Rao VM, Haslam JL, Stella VJ. Controlled and complete release of a model poorly water-soluble drug, prednisolone from hydroxypropyl methylcellulose matrix tablets using (SBE) (7m)-beta-cyclodextrin as a solubilizing agent. J Pharm Sci. 2001;90:807-816.
164. Fernandes CM, Teresa Viera M, Veiga FJ. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci. 2002;15:79-88.
165. Fernandes CM, Ramos P, Falcao AC, Veiga FJ. Hydrophilic and hydrophobic cyclodextrins in a new sustained release oral formulation of nicardipine: in vitro evaluation and bioavailability studies in rabbits, J Control Release. 2003;88:127-134.
166. Chowdary KPR, Reddy GK. Complexes of nifedipine, with β- and hydroxypropyl-β-cyclodextrin in the design of nifedipine SR tablets. Ind J Pharm Sci. 2002;64:142-146.
167. Burgos AE, Belchior JC, Sinisterra RD. Controlled release of rhodium (II) carboxylates and their association complexes with cyclodextrins from hydroxyapatite matrix. Biomaterials. 2002;23:2519-2526.
168. Minami K, Hirayama F, Uekama K. Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. J Pharm Sci. 1998;87:715-720.
169. Hirayama F, Ogata T, Yano H, et al, Release characteristics of a short-chain fatty acid, n-butyric acid from its beta-cyclodextrin ester conjugate in rat biological media. J Pharm Sci. 2000;89:1486-1495.
170. Yano H, Hirayama F, Kamada M, Arima H, Uekama K, Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J Control Release. 2002;79:103-112.
171. Lopez MEV, Reyes LN, Igea SA, Espinar FJO, Mendez JB. Formulation of triamcinolone acetonide pellets suitable for coating and colon targeting. Int J Pharm. 1999-179:229-235.
172. Irie T, Uekama K. Cyclodextrins in peptide and protein delivery. Adv Drug Deliv Rev. 1999;36:101-123.
173. Augustijns PF, Bradshaw TP, Gan LSL, Hendren RW, Thakker DR. Evidence for a polarized efflux system in caco-2 cells capable of modulating cyclosporin a transport. Biochem Biophys Res Commun. 1993;197:360-365.
174. Burton PS, Conradi RA, Hilgers AR, Ho NFH. Evidence for a polarized efflux system for peptides in the apical membrane of caco-2 cells, Biochem Biophys Res Commun. 1993;190:760-766.
175. Ueda K, Shimabuku AM, Konishi H, et al. Functional expression of human P-glycoprotein in Schizosaccharomyces pombe. FEBS Lett. 1993;330:279-282.
176. Loe DW, Sharom FJ. Interaction of multidrug-resistant Chinese hamster ovary cells with the peptide ionophore gramicidin D. Biochim Biophys Acta. 1994;1190:72-84.
177. Takahashi H, Kim RB, Perry PR, Wilkinson GR. Characterization of the hepatic canalicular membrane transport of a model oligopeptide: ditekiren1. J Pharm Exp Therapeutics. 1997;281:297-303.
178. Sharom FJ, Xiaohong YU. DioDiodato G, Chu JWK. Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. Biochem J. 1996;320:421-428.
179. McNally EJ, Park JY. Peptides and Proteins - Oral Absorption. In: Swarbrick J, Boylan JC, eds. Encyclopedia of Pharmaceutical Technology 2nd ed. New York, NY: Marcell Dekker; 2002:2096-2113.
180. Arima H, Yunomae K, Morikawa T, Hirayama F, Uekama K. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-β-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharm Res, 2004;21:625-634.
181. Arima H, Yunomae K, Hirayama F, Uekama K. Contribution of P-glycoprotein to the enhancing effects of dimethyl-β-cyclodextrin on oral bioavailability of Tacrolimus. J Pharm Exp Therapeutics. 2001;297:547-555.
182. Verhoef JC, Schipper NGM, Romeijn SG, Merkus FWHM. The potential of cyclodextrins as absorption enhancers in nasal delivery of peptide drugs. J Control Release. 1994;29:351-360.
183. Jerry N, Anitha Y, Sharma CP, Sony P. In vivo absorption studies of insulin from an oral delivery system. Drug Deliv. 2001;8:19-23.
184. Dass CR. Vehicles for oligonucleotide delivery. J Pharm Pharmacol. 2002:54:3-27.
185. Redenti E, Pietra C, Gerlozy A, Szente L. Cyclodextrins in oligonucleotide delivery. Adv Drug Deliv Rev. 2001;53:235-244.
186. Driscoll CO, Darcy R. Cyclodextrin constructs for delivery of genotherapuetic agents. Business Briefing Pharmatech 2002 Available at: http://www.bbriefings.com/pdf/17/ACF9C6C.pdf.Accessed May 25, 2005.
187. Hwang SJ, Bellocq NC, Davis ME. Effects of structure of β-cyclodextrin-containing polymers on gene delivery. Bioconjugate Chem. 2001;12:280-290.
188. Pun SH, Davis DE. Development of a nonviral gene delivery vehicle for systemic application, Bioconjugate Chem, 2002;13:630-639.
189. Croyle MA, Roessler BJ, Hsu CP, Sun R, Amidon GL. Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine, Pharm Res. 1998;15:1348-1355.
190. Lopez RF, Collett JH, Bently MV. Influence of cyclodextrin complexation on the in vitro permeation and skin metabolism of dexamethasone. Int J Pharm. 2000:200:127-132.
191. Orienti I, Zecchi V, Bernabei S, Sentimenti S, Fini A. Diffusion of ketoprofen from coprecipitates through a non porous lipidic membrane. Boll Chim Farm. 1989;128:336-343.
192. Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm. 2001;225:15-30.
193. Chang SL, Banga AK. Transdermal iontophoretic delivery of hydrocortisone from cyclodextrin solutions. J Pharm Pharmacol. 1998;50:635-640.
194. Doliwa A, Santoyo S, Ygartua P. Transdermal iontophoresis and skin retention of piroxicam from gels containing piroxicam: hydroxypropyl-beta-cyclodextrin complexes. Drug Dev Ind Pharm. 2001;27:751-758.
195. Tanaka M, Matsuda H, Sumiyoshi H. et al. 2-Hydroxy- propylated cyclodextrins as a sustained release carrier for fragrance materials. Chem Pharm Bull (Tokyo). 1996;44:416-420.
196. Buschmann HJ, Schollmeyer E. Applications of cyclodextrins in cosmetic products: a review. J Cosmet Sci. 2002;53:185-191.
197. Brewster ME, Loftsson T, The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems. Pharmazie. 2002;57:94-101.
198. Wu Wm, Wu J, Bodor N. Effect of 2-hydroxypropyl-beta-cyclodextrin on the solubility, stability, and pharmacological activity of the chemical delivery system of TRH analogs. Pharmazie. 2002;57:130-134.
199. McCormack B, Gregoriadis G. Entrapment of cyclodextrin-drug complexes into liposomes: Potential advantages in drug delivery. J Drug Target. 1994;2:449-454.
200. McCormack B, Gregoriadis G. Drugs-in-cyclodextrins-in-liposomes: an approach to controlling the fate of water insoluble drugs in vivo. Int J Pharm. 1998;162:59-69.
201. McCormack B, Gregoriadis G. Drugs-in-cyclodextrins-in liposomes: a novel concept in drug delivery. Int J Pharm. 1994; 112:249-258.
202. Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting. Application to nanoparticles. Adv Drug Del Rev. 1999;36:29-40.
203. McCormack B, Gregoriadis G. Comparative studies of the fate of free and liposome-entrapped hydroxypropyl-β-cyclodextrin/drug complexes after intravenous delivery into rats: Implications in drug delivery. Biochim Biophys Acta. 1996;1291:237-244.
204. Skalko N, Brandl M, Ladan MB, Grid JF, Genjak IJ. Liposomes with nifedipine and nifedipine-cyclodextrin complex: calorimetrical and plasma stability comparison. Eur J Pharm Sci. 1996;4:359-366.
205. Fatouros DG, Hatzidimitriu K, Antimisiaris SG. Liposomes encapsulating prednisolone-cyclodextrin complexes: comparision of membrane integrity and drug release. Eur J Pharm Sci. 2001;13:287-296.
206. Skalko-Basnet N, Pavelic Z, Becirevic-Lacan M. Liposomes containing drug and cyclodextrin prepared by the one-step spray-drying method. Drug Dev Ind Pharm. 2000;126:1279-1284.
207. Loukas YL, Jayasekera R Gregoriadis G. Novel liposome-based multicomponent systems for the protection of photolabile agents. Int J Pharm. 1995;117:85-94. doi: 10.1016/0378-5173(94)00320-5
208. Loukas YL, Vraka V, Gregoriadis G. Drugs, in cyclodextrins, in liposomes: a novel approach to the chemical stability of drugs sensitive to hydrolysis. Int J Pharm. 1998;162:137-142.
209. Sukegawa T, Furuike T, Niikura K, Yamagishi A, Monde K, Nishimura S. Erythrocyte-like liposomes prepared by means of amphiphilic cyclodextrin sulfates. Chem Commun. 2002;5:430-431.
210. Filipovic-Grcic J, Laan MB, Skalko N, Jalsenjak I. Chitosan microspheres of nifedipine and nifedipine-cyclodextrin inclusion complexes. Int J Pharm. 1996;135:183-190.
211. Filipovic-Grcic J, Voinovich D, Moneghini M, Becirevic-Lacan M, Magarotto L, Jalsenjak I. Chitosan Pharm Sci. 2000;9:373-379.
212. Bibby DC, Davies NM, Tucker IG. Investigations into the structure and composition of beta-cyclodextrin/poly (acrylic acid) microspheres. Int J Pharm. 1999;180:161-168.
213. Bibby DC, Davies NM, Tucker IG. Poly (acrylic acid) microspheres containing β-cyclodextrin: loading and in vitro release of two dyes. Int J Pharm. 1999;187:243-250.
214. Kang F, Jiang G, Hinderliter A, Luca PPD, Singh J. Lysozyme stability in primary emulsion for PLGA microsphere preparation: effect of recovery methods and stabilizing excipients. Pharm Res. 2002;19:629-633.
215. Kang F, Singh J. Conformational stability of a model protein (bovine serum albumin) during primary emulsification process of PLGA microspheres synthesis. Int J Pharm. 2003;260:149-156.
216. Quaglia F, De Rosa G, Granata E, Ungaro F, Fattal E, La Rotonda MI. Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray-drying. J Control Release, 2003;86:267-278.
217. Fundueanu G, Constantin M, Dalpiaz A, et al. Preparation and characterization of starch/cyclodextrin bioadhesive microspheres as platform for nasal administration of Gabexate Mesylate (Foy®) in allergic rhinitis treatment. Biomaterials. 2004;25:159-170.
218. Constantin M, Fundueanu G, Bortolotti F, Cortesi R, Ascenzi P, Menegatti E, Preparation and characterisation of poly(vinyl alcohol)/ cyclodextrin microspheres as matrix for inclusion and separation of drugs. Int J Pharm. 2004;285:87-96.
219. Pariot N, Levy FE, Andry MC, Levy MC. Cross-linked beta-cyclodextrin microcapsules. II. Retarding effect on drug release through semi-permeable membranes. Int J Pharm. 2002;232:175-181.
220. Memisoglu E, Bochot A, Sen M, Duchene D, Hincal AA. Non-surfactant nanospheres of progesterone inclusion complexes with amphiphilic β-cyclodextrins. Int J Pharm. 2003;251:143-153.
221. Monza da Silveira A, Ponchel G, Puisieux F, Duchene D. Combined poly (isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm Res. 1998;15:1051-1055.
222. Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting Application to nanoparticles. Adv Drug Deliv Rev. 1999;36:29-40.
223. Boudad H, Legrand P, Lebas G, Cheron M, Duchene D, Ponchel G. Combined hydroxypropyl-beta-cyclodextrin and poly (alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm. 2001;1218:113-124.
224. Radwan MA. Preparation and in vivo evaluation of parenteral metoclopramide-loaded poly (alkylcyanoacrylate) nanospheres in rats. J Microencapsul. 2001;18:467-477.
225. Cavalli R, Peira E, Caputo O, Gasco MR. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with beta-cyclodextrins. Int J Pharm. 1999;182:59-69.
226. Memisoglu E, Bochot A, Sen M, Charon D, Duchene D, Hincal AA. Amphiphilic beta-cyclodextrins modified on the primary face: synthesis, characterization, and evaluation of their potential as novel excipients in the preparation of nanocapsules. J Pharm Sci. 2002;91:1214-1224.
227. Memisoglu E, Bochot A, Ozalp M, Sen M, Duchene D, Hincal AA. Direct formation of nanospheres from amphiphilic beta-cyclodextrin inclusion complexes. Pharm Res. 2003;20:117-125.
228. Gèze A, Aous S, Baussanne I, Putaux JL, Defaye J, Wouessidjewe D. Influence of chemical structure of amphiphilic β-cyclodextrins on their ability to form stable nanoparticles. Int J Pharm. 2002; 242:301-305.
229. Shangraw RF, Pande GS, Gala P. Charactarisation of the tableting properties of beta cycloldextrin: the effects of processing variableson the inclusion complex formation, compactability and dissolution. Drug Dev Ind Pharm. 1992;18:1831-1851.
230. Suihko E, Korhoneno O, Jarvinen T, et al. Complexation with tolbutamide modifies the physicochemical and tableting properties of hydroxypropyl-beta-cyclodextrin, Int J Pharm. 2001;215:137-145.
231. Tsai T, Wu JS, Ho HO, Sheu MT. Modification of physical characteristics of microcrystalline cellulose by codrying with beta-cyclodextrins. J Pharm Sci. 1998;87:117-122.
232. Li WD, Huang JC, Corke H. Effect of beta-cyclodextrin on pasting properties of wheat starch. Nahrung. 2000;44:164-167.
233. Wu J, Ho H, Sheu M. Influence of wet granulation and lubrication on the powder and tableting properties of codried product of microcrystalline cellulose with beta-cyclodextrin. Eur J Pharm Biopharm. 2001;151:63-69.
234. Gazzaniga A, Sangalli ME, Bruni G, Zema L, Vecchio C, Giordano F, The use of beta-cyclodextrin as a pelletization agent in the extrusion/ spheronization process. Drug Dev Ind Pharm. 1998;24:869-873.
235. Branchu S, Forbes RT, York P, Petren S, Nyquest H, Camber O. Hydroxypropyl-beta-cyclodextrin inhibits spray-drying-induced inactivation of beta-galactosidase. J Pharm Sci. 1999;88:905-911.
236. Tokihiro K, Irie T, Uekama K, Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution. Chem Pharm Bull (Tokyo). 1997;45:525-531.
237. Kitamura S, Fujimura T, Kohda S. Interaction between surface-active drug (FK906, rennin inhibitor) and cyclodextrins in aqueous solution. J Pharm Sci. 1999;88:327-330.
238. Blanco-Fuente H, Esteban-Fernandez B, Blanco-Mendez J, Otero-Espinar FJ. Use of beta-cyclodextrins to prevent modifications of the properties of carbopol hydrogels due to carbopol-drug interactions. Chem Pharm Bull (Tokyo). 2002;50:40-46.
239. Muñoz-Ruiz AM, Paronen P. Particle and powder properties of cyclodextrins. Int J Pharm. 1997;148:33-39.
240. Zannou EA, Streng WH, Stella VJ. Osmotic properties of sulfobutylether and hydroxypropyl cyclodextrins. Pharm Res. 2001;18:1226-1231. doi: 10.1023/A:1010947631380
241. Proniuk S, Blanchard J. Influence of degree of substitution of cyclodextrins on their colligative properties in solution. J Pharm Sci. 2001;90:1086-1090.
242. Loftsson T, Stefansdottir O, Friariksdottir H, Guomundsson O. Interaction between preservatives and 2-hydroxypropyl β-cyclodextrin. Drug Dev Ind Pharm. 1992;18:1477-1484.